NCT05668403View on ClinicalTrials.gov

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Primary Membranous Nephropathy
Interventions
DRUG

B007

Drug: B007 injection Drug: Placebo injection

DRUG

B007

Drug: B007 injection Drug: Placebo injection

DRUG

B007

Drug: B007 injection Drug: Placebo injection

Trial Locations (6)

100010

RECRUITING

Peking university first hospital, Beijing

200032

RECRUITING

Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai

RECRUITING

Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai

310003

RECRUITING

The First Affiliated Hospital,College of Medicine,Zhejiang University, Hangzhou

410100

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

050057

RECRUITING

Hebei General Hospital, Shijiazhuang

All Listed Sponsors
collaborator

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

lead

Shanghai Jiaolian Drug Research and Development Co., Ltd

INDUSTRY